Advertisement

Lung

pp 1–3 | Cite as

Iftikhar and Colleagues Reply: Methodology Clarified

  • Imran H. Iftikhar
  • Mathew Schimmel
  • William Bender
  • Colin Swenson
  • David Amrol
LETTER TO THE EDITOR
  • 13 Downloads

We thank Gunsoy and colleagues for their comments on our paper [1] and appreciate the opportunity to further clarify our methods and results. The definitions of asthma exacerbations differed in different studies and was provided in each article mostly in their ‘methods’ sections. Yes, it is true, that we ‘did not extract treatment effects’ directly from the source articles. We simply used the asthma exacerbation data reported in each study (see Table for further clarification) in our meta-analysis. We never reported that some biologics increased asthma exacerbations as Gunsoy et al. imply. It is true that ‘patient-years’ were not provided in each study, which is why we specified in the methods section, that we calculated the patient-years based on the data on follow-up provided in each study. However, it is not true, that exacerbation rates were not reported ‘within most studies’ (see Table). For Chupp et al. [2], Bel et al. [3], and Castro et al. [4] studies, the asthma exacerbation...

Notes

Compliance with Ethical Standards

Conflict of interest

The authors declare that they have no competing interests.

References

  1. 1.
    Iftikhar IH, Schimmel M, Bender W, Swenson C, Amrol D (2018) Comparative efficacy of anti IL-4, IL-5 and IL-13 drugs for treatment of eosinophilic asthma: a network meta-analysis. Lung 196:517–530CrossRefGoogle Scholar
  2. 2.
    Chupp GL, Bradford ES, Albers FC, Bratton DJ, Wang-Jairaj J, Nelsen LM, Trevor JL, Magnan A, Ten Brinke A (2017) Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med 5:390–400CrossRefGoogle Scholar
  3. 3.
    Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, Ortega HG, Pavord ID, Investigators S (2014) Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 371:1189–1197CrossRefGoogle Scholar
  4. 4.
    Castro M, Zangrilli J, Wechsler ME, Bateman ED, Brusselle GG, Bardin P, Murphy K, Maspero JF, O’Brien C, Korn S (2015) Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med 3:355–366CrossRefGoogle Scholar
  5. 5.
    Nair P, Wenzel S, Rabe KF, Bourdin A, Lugogo NL, Kuna P, Barker P, Sproule S, Ponnarambil S, Goldman M et al (2017) Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med 376:2448–2458CrossRefGoogle Scholar
  6. 6.
    Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, Ortega H, Chanez P (2012) Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 380:651–659CrossRefGoogle Scholar
  7. 7.
    Hanania NA, Korenblat P, Chapman KR, Bateman ED, Kopecky P, Paggiaro P, Yokoyama A, Olsson J, Gray S, Holweg CT et al (2016) Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir Med 4:781–796CrossRefGoogle Scholar
  8. 8.
    Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, Busse WW, Ford L, Sher L, FitzGerald JM et al (2018) Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med 378:2486–2496CrossRefGoogle Scholar
  9. 9.
    Rabe KF, Nair P, Brusselle G, Maspero JF, Castro M, Sher L, Zhu H, Hamilton JD, Swanson BN, Khan A et al (2018) Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med 378:2475–2485CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Imran H. Iftikhar
    • 1
  • Mathew Schimmel
    • 1
  • William Bender
    • 1
  • Colin Swenson
    • 1
  • David Amrol
    • 2
  1. 1.Division of Pulmonary, Allergy, Critical Care & Sleep MedicineEmory University School of MedicineAtlantaUSA
  2. 2.Division of Allergy and ImmunologyUniversity of South Carolina School of MedicineColumbiaUSA

Personalised recommendations